Centessa Pharmaceuticals PLCNASDAQ:CNTA
- LAST PRICE8.8700
- TODAY'S CHANGE (%)-0.0200 (-0.2250%)
- Bid / Lots8.8500/ 1
- Ask / Lots8.8900/ 1
- Open / Previous Close8.8300 / 8.8900
- Day Range
- 52 Week Range
- Volume22,741
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNTA |
|---|---|---|
| 09:32 ET | 480 | 8.83 |
| 09:34 ET | 3279 | 8.82 |
| 09:36 ET | 400 | 8.85 |
| 09:38 ET | 400 | 8.805 |
| 09:41 ET | 900 | 8.805 |
| 09:43 ET | 2139 | 8.85 |
| 09:45 ET | 100 | 8.8 |
| 09:48 ET | 3718 | 8.82 |
| 09:50 ET | 3349 | 8.76 |
| 09:52 ET | 200 | 8.79 |
| 09:54 ET | 286 | 8.86 |
| 09:56 ET | 200 | 8.835 |
| 09:57 ET | 100 | 8.845 |
| 09:59 ET | 600 | 8.85 |
| 10:01 ET | 800 | 8.87 |
Jun 21, 2024
DJ Centessa Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley, from 10:25AM ET on Friday Jun 21, 2024 by Dow Jones
10:25AM ET on Friday Jun 21, 2024 by Dow Jones
Jun 10, 2024
DJ Centessa Pharma Hires CFO from Fusion After AstraZeneca Takeover, from 7:37AM ET on Monday Jun 10, 2024 by Dow Jones
7:37AM ET on Monday Jun 10, 2024 by Dow JonesCentessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer, from 7:00AM ET on Monday Jun 10, 2024 by Dow Jones
7:00AM ET on Monday Jun 10, 2024 by Dow JonesPress Release: Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer, from 7:00AM ET on Monday Jun 10, 2024 by Dow Jones
7:00AM ET on Monday Jun 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Centessa Pharmaceuticals PLC | 1.0B | -6.3x | --- |
Enliven Therapeutics Inc | 1.0B | -10.8x | --- |
Cullinan Therapeutics Inc | 946.4M | -5.1x | --- |
Autolus Therapeutics PLC | 925.8M | -2.9x | --- |
Cassava Sciences Inc | 925.5M | -16.4x | --- |
Bicycle Therapeutics PLC | 995.1M | -4.5x | --- |
Company Information
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Contact Information
- Headquarters
- 3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Francesco de Rubertis
- Chief Executive Officer, Director
- Saurabh Saha
- Chief Financial Officer
- John Crowley
- Chief People Officer
- Karen Anderson
- Executive Vice President and Chairman of Development
- Antoine Yver
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
|---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 113.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.42 |
Book Value | $2.39 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | 146.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,312.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
